Etoposide (VP 16-213) — a podophyllotoxinderivative with high antitumor activity

Cisplatin : current status and new developments

1980 • 746 citations

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

1979 • 405 citations

Cancer chemotherapy handbook

1980 • 283 citations

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

1976 • 197 citations

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1976 • 187 citations

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors

1973 • 184 citations

The Biological Effects and the Chemical Composition of Podophyllin. A Review

1954 • 181 citations

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

1978 • 166 citations

Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin

1971 • 163 citations

Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives

1978 • 160 citations

cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.

1979 • 153 citations

Etoposide (VP-16-213)

1979 • 151 citations

SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIA

1973 • 148 citations

Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.

1978 • 142 citations

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

1979 • 142 citations

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.

1975 • 133 citations

VM 26 and VP 16–213: A comparative analysis

1977 • 122 citations

Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells.

1976 • 120 citations

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1974 • 118 citations

Cancer Chemotherapy Handbook.

1980 • 113 citations

Conformational analysis of podophyllotoxin and its congeners. Structure-activity relationship in microtubule assembly

1979 • 113 citations

VP16-213 as a single agent in advanced testicular tumors

1980 • 112 citations

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1975 • 109 citations

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.

1976 • 102 citations

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1975 • 97 citations

Pyogenic cocci in infantile eczema throughout one year.

1975 • 88 citations

Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid Tumours

1973 • 88 citations

Rationale for development of platinum analogs.

1979 • 86 citations

Podophyllotoxin derivative VP 16-213

1979 • 86 citations

Teratogenic and cytogenetic effects of some plant‐derived antitumor agents (vincristine, colchicine, maytansine, VP‐16‐213 and VM‐26) in mice

1978 • 86 citations

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1975 • 85 citations

Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.

1979 • 83 citations

Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro.

1974 • 77 citations

Cell cycle stage-dependent induction of G2 phase arrest by different antitumor agents

1978 • 71 citations

Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

1980 • 69 citations

Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II).

1976 • 69 citations

Chemotherapy of small cell carcinoma of the lung with V. P. 16–213

1978 • 65 citations

EPEG, a new antineoplastic epipodophyllotoxin

1975 • 64 citations

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1977 • 58 citations

Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinoma

1980 • 56 citations

VP 16-213 in acute myelogenous leukaemia

1976 • 55 citations

Testicular Tumors—Management and Treatment

1981 • 55 citations

The Cytological Effects of Podophyllin

1947 • 53 citations

Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoietic cell lines.

1973 • 53 citations

Combination chemotherapy with 4′Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 Leukemia

1976 • 52 citations

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.

1977 • 52 citations

Antineoplastic Drugs

1978 • 49 citations

Combination chemotherapy for small cell carcinoma of the lung

1977 • 48 citations

Pharmacology of antitumor agents from higher plants.

1976 • 47 citations

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

1978 • 47 citations

Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.

1972 • 45 citations

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

1976 • 45 citations

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

1981 • 44 citations

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

1972 • 42 citations

Radiation recall associated with VP-16-213 therapy.

1979 • 39 citations

Antitumor activity of cis-dichlorodiammineplatinum(II).

1979 • 36 citations

Activity of the Epipodophyllotoxin VP‐16 in the Treatment of Combination Chemotherapy‐Resistant Non‐Hodgkin Lymphoma

1978 • 35 citations

Evaluation of VP-16-213 in malignant lymphoma and melanoma.

1978 • 34 citations

4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.

1975 • 33 citations

Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures.

1977 • 30 citations

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

1975 • 30 citations

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

1979 • 28 citations

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents

1978 • 27 citations

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.

1976 • 26 citations

PHASE I clinical trial of an oral solution of VP-16-213.

1976 • 25 citations

Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16-213), due to a local effect

1976 • 24 citations

Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both.

1975 • 24 citations

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.

1976 • 23 citations

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

1974 • 23 citations

Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.

1976 • 21 citations

Phase I trial of a new form of an oral administration of VP-16-213.

1979 • 21 citations

Evaluation of VP-16 and the Combination of Adriamycin and Vincristine in Advanced Breast Cancer

1976 • 20 citations

Response of Patients with Advanced Neoplasms to the Intravenous Administration of <italic>Alpha</italic>-Peltatin<xref ref-type="fn" rid="fn1">2</xref>

1954 • 20 citations

RATIONALE OF COMBINATION CHEMOTHERAPY

1980 • 20 citations

Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076).

1966 • 18 citations

Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.

1975 • 17 citations

Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.

1973 • 16 citations

Human anticancer effect of podophyllum derivatives (SPG and SPI): a preliminary report.

1967 • 15 citations

[Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].

1975 • 13 citations

[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].

1977 • 12 citations

[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].

1975 • 9 citations

Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomas.

1977 • 8 citations

Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275).

1979 • 8 citations

Die Kombination Ifosfamid/VP 16-213 bei der Therapie des kleinzelligen Bronchialkarzinoms und anderer Malignome

1980 • 7 citations

Treatment of cutaneous carcinoma with podophyllin.

1949 • 7 citations

CISPLATIN ANALOGS AND COMBINATION CHEMOTHERAPY IN THE THERAPY OF MURINE BLADDER CANCER

1980 • 7 citations

Incompatibilities with parenteral anticancer drugs

1979 • 7 citations

Erfolgreiche Behandlung der chronischen myelomonozyt�ren Leuk�mie mit VP 16-213

1979 • 5 citations

Chronic myelomonocytic leukaemia: a case report.

1977 • 4 citations

Chronic Myelomonocytic Leukaemia

1977 • 4 citations

Epipodophyllotoxin (VP 16-213) in the treatmetn of diffuse histiocytic lymphoma.

1975 • 3 citations

[Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)].

1974 • 3 citations

Die Behandlung des kleinzelligen Bronchialkarzinoms mit einer neuen Kombinationschemotherapie (VPIV)

1980 • 3 citations

Zusammenfassung

1976 • 1 citations

Deleted Work

1955 • 0 citations